These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 14564081)
21. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Doi H; Kugiyama K; Ohgushi M; Sugiyama S; Matsumura T; Ohta Y; Nakano T; Nakajima K; Yasue H Atherosclerosis; 1998 Apr; 137(2):341-9. PubMed ID: 9622277 [TBL] [Abstract][Full Text] [Related]
22. Filtration of chylomicrons by the liver may influence cholesterol metabolism and atherosclerosis. Fraser R; Bosanquet AG; Day WA Atherosclerosis; 1978 Feb; 29(2):113-23. PubMed ID: 206268 [TBL] [Abstract][Full Text] [Related]
23. [Oxidized dietary lipids may participate in the development of atherosclerosis]. Bałasińska B; Mazur A Postepy Hig Med Dosw (Online); 2004 Mar; 58():176-82. PubMed ID: 15280795 [TBL] [Abstract][Full Text] [Related]
26. Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall. Öörni K; Lehti S; Sjövall P; Kovanen PT Curr Med Chem; 2019; 26(9):1701-1710. PubMed ID: 29848270 [TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult? Chung BH; Segrest JP Adv Exp Med Biol; 1991; 285():341-51. PubMed ID: 1858566 [TBL] [Abstract][Full Text] [Related]
28. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis? Chung BH; Segrest JP; Smith K; Griffin FM; Brouillette CG J Clin Invest; 1989 Apr; 83(4):1363-74. PubMed ID: 2703536 [TBL] [Abstract][Full Text] [Related]
29. Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Elsegood CL; Pal S; Roach PD; Mamo JC Clin Sci (Lond); 2001 Aug; 101(2):111-9. PubMed ID: 11473484 [TBL] [Abstract][Full Text] [Related]
30. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Sattar N; Petrie JR; Jaap AJ Atherosclerosis; 1998 Jun; 138(2):229-35. PubMed ID: 9690905 [TBL] [Abstract][Full Text] [Related]
31. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. Choi SY; Fong LG; Kirven MJ; Cooper AD J Clin Invest; 1991 Oct; 88(4):1173-81. PubMed ID: 1918372 [TBL] [Abstract][Full Text] [Related]
32. Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Yu KC; Mamo JC Clin Sci (Lond); 2000 Feb; 98(2):183-92. PubMed ID: 10657274 [TBL] [Abstract][Full Text] [Related]
33. Inflammatory reactions in the pathogenesis of atherosclerosis. Fan J; Watanabe T J Atheroscler Thromb; 2003; 10(2):63-71. PubMed ID: 12740479 [TBL] [Abstract][Full Text] [Related]
34. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Shin HK; Kim YK; Kim KY; Lee JH; Hong KW Circulation; 2004 Mar; 109(8):1022-8. PubMed ID: 14967724 [TBL] [Abstract][Full Text] [Related]